Immune Impact of Bevacizumab in Patients with Recurrent

Recruiting

99 years or below

All

40 participants needed

1 Location

Brief description of study

PURPOSE/DESCRIPTION: Primary: to perform high-dimensional flow cytometry on peripheral blood of patients with recurrent glioblastoma receiving standard of care anti-VEGF therapy with bevacizumab to understand the immune impact of the drug on various immune cell populations. Secondary: To perform an evaluation of ex vivo cytokine production in peripheral blood T Cells for IL-2, IFN-gamma, and TNF-alpha after PMA/ionomycin or CD 3+ stimulation. To perform intracellular measurement of TOX transcription factor levels in peripheral blood immune cells Expression level of surface markers on peripheral blood immune cells before and after bevacizumab therapy 1. Ex-vivo cytokine production after stimulation 2. Intra cellular TOX protein levels

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 99 years or below
Gender: All

Updated on 17 Jan 2023. Study ID: 848487

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Immune Impact of Bevacizumab in Patients with Recurrent Glioblastoma

Brief description of study

Eligibility of study

Find a site

Interested in the study